Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Agriculture Fund (DBA) vs Davita Inc (DVA) Price & Performance

Invesco DB Agriculture FundTrade
Davita IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Agriculture Fund vs Davita Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.33B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Davita Inc is far larger — about 8.5× Invesco DB Agriculture Fund's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Davita Inc for 113 Days on average.

DBADVA
Market Cap
$1.33B$11.28B
Volume
991,157650,294
52-Week High
$29.49$240.96
52-Week Low
$25.44$103.87
Typical Hold Time
24 Days113 Days
Sector
—Health
Enterprise Value
—$24.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Agriculture Fund

DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong YTD performance with 12.4% returns. The technical outlook remains bullish with moving averages signaling strength, though oscillators show neutral momentum. Recent news highlights agricultural ETF outperformance driven by weather risks and geopolitical tensions supporting commodity prices.

The fund's diversified agricultural futures exposure and 3.25% yield provide defensive characteristics amid market volatility. Key risks include high expense ratios (0.85%) and commodity price sensitivity. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish consolidation near all-time highs since 2020.

Davita Inc

DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.

The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DBA
58% Buy42% Sell
Avg holding period · 24 Days
DVA
91% Buy9% Sell
Avg holding period · 113 Days

Top news

Latest headlines on both assets

About Invesco DB Agriculture Fund

The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.

Read more on DBA →

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →